Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 29, 2005BloodOpen Access

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDavid P. SteensmaTwitter (United States)GDGordon W. DewaldMayo Clinic in ArizonaTLTerra L. LashoMayo Clinic

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Steensma et al. (2005) studied this question.

synapsesocial.com/papers/6a0dcc61cecdf5fb20ba9bf2https://doi.org/10.1182/blood-2005-03-1183
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.2004 · 52 citations
  2. 2World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 19971999 · 3,290 citations